



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/02, G01N 33/564, 33/566,</b> <b>33/569, 33/574</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/20155</b> <b>(43) International Publication Date:</b> 14 May 1998 (14.05.98)
<b>(21) International Application Number:</b> PCT/US97/20540 <b>(22) International Filing Date:</b> 7 November 1997 (07.11.97)  <b>(30) Priority Data:</b> 60/029,719 8 November 1996 (08.11.96) US  <b>(71) Applicant:</b> NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY [US US], 535 East 70th Street, New York, NY 10021 (US).  <b>(72) Inventors:</b> CROW, Mary, K.; 17 East 89th Street, New York, NY 10028 (US). VAKKALANKA, Radha, Krishna, 525 East 71st Street, New York, NY 10021 (US).  <b>(74) Agents:</b> LUDWIG, S., Peter et al., Darby & Darby P.C., 805 Third Avenue, New York, NY 10022 (US).		<b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> DIAGNOSTIC METHODS USING CD40 LIGAND ASSAY  <b>(57) Abstract</b>  The present invention provides diagnostic methods for determining the severity of disease or disease activity in patients suffering from autoimmune, inflammatory, malignant, vascular, or viral diseases, which involves measuring the level of CD40 ligand (CD40L) in the patient's serum or other body fluid.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

**DIAGNOSTIC METHODS USING CD40 LIGAND ASSAY**

This application claims priority pursuant to 35 U.S.C. §119 from Provisional  
10 Application Serial No. 60/029,719 filed November 8, 1996, the entire disclosure of which  
is hereby incorporated by reference.

15 **Field of Invention**

This invention pertains to methods for assessing autoimmune, inflammatory,  
malignant or vascular disease activity in humans, including methods for assessing response  
to immunosuppressive therapies.

20 **Background of the Invention**

The activation of B cells and their differentiation into antibody secreting  
cells is triggered by antigen and requires T helper (Th) cells. Not only do Th cells control  
activation of B cells, they also control isotype switching (IgM to IgG) and initiate somatic  
hypermutation. (Janeway et al., *Immunobiology*, Garland Publishing, New York, 1997).  
25 Th cells also play an important role in activating macrophages and in coordinating the  
response of the host to intracellular pathogens.

The proteins most responsible for controlling the interaction between Th  
cells and various target cells are CD40 and CD40 ligand (CD40L). Interaction of  
membrane-bound CD40 and CD40L triggers B-cell activation. Preventing formation of the  
30 CD40-CD40L complex (as with, e.g., monoclonal antibodies) has been shown to inhibit  
(i) murine AIDS-associated splenomegaly, hypergammaglobulinemia, and  
immunodeficiency in disease-susceptible mice (Green et al. *J. Virol.* **70**:2569, 1996); (ii)  
insulinitis and diabetes in nonobese diabetic mice (Balasa et al. *J. Immunol.* **159**:4620,

1997); (iii) murine thyroiditis (Carayanniotis et al. *Immunology* 90:421, 1997); (iv) CD4+ T cell mediated alloreactivity after bone marrow transplantation (Blazar et al., *J. Immunol.* 158:29, 1997); (v) the immune response to infection with recombinant adenovirus (Kay et al., *Proc. Natl. Acad. Sci. U.S.A.* 94:4686, 1997); (vi) allograft rejection of transplanted skin or cardiac tissue (Larsen et al. *Nature* 381:434, 1996); (vii) murine membranous glomerulonephritis (Biancone et al. *Kidney Intl.* 48:458, 1995); and (viii) lupus-nephritis in a murine model of systemic lupus erythematosus (Early et al. *J. Immunol.* 157:3159, 1996). Thus, it is clear that the interaction CD40 and CD40L plays an important role in normal and pathological immune system function.

CD40L is expressed in T cells, activated B cells, a subpopulation of blood dendritic cells, smooth muscle cells, and vascular endothelial cells and, importantly, is present as a soluble form in the blood (Grammar et. al., *J. Immunol.* 154:4996, 1995; Blossom et. al., *J. Immunol.* 159:4580, 1997; Pinchuk et. al., *J. Immunol.* 157:4363, 1996; and, Mach et. al., *Proc. Natl. Acad. Sci. USA* 94: 1931, 1997). Furthermore, the present inventors have found that CD40L is expressed in malignant cells, including, for example B cell malignancies such as chronic lymphocytic leukemia (CLL). The expression of CD40L on endothelial cells and smooth muscle cells also suggests that this protein plays an important role in the induction of vascular damage, as is observed, for example, in atherosclerosis or thrombosis (Mach et al., *Proc. Natl. Acad. Sci. USA* 94:1931, 1997). Because of the importance of CD40L in a wide range of diseases or disease processes, such as, e.g., inflammation, there is a need in the art for a reliable diagnostic and prognostic method to monitor disease activity and response to therapy, by assaying the expression or presence of CD40L.

CD40L is a 261-amino acid type II transmembrane protein. One or more biologically active soluble forms of the molecule, collectively designated sCD40L,

are produced by proteolytic cleavage of the full-length form, which may occur intracellularly or on the cell surface. sCD40L is important in inflammation. For example, an sCD40L fusion protein (CD40L-CD8) induced a pulmonary inflammatory response in transgenic mice expressing the soluble protein. (Wiley et al. *J. Immunol.* **158**:2932 (1997).

5

When a patient is diagnosed with an autoimmune disease such as sytemic lupus erythematosus (SLE), a B cell malignancy such as CLL, an inflammatory process, or a vascular disease such as atherosclerosis or thrombosis, the choicc of appropriate therapeutic interventions would be considerably facilitated by diagnostic and prognostic indicators that accurately reflect the current severity of the disease, predict future severity, and monitor response to therapy. Thus, there is a need in the art for reliable diagnostic and prognostic methods to monitor disease activity and response to therapy in patients suffering from autoimmune disease.

## 15 Summary of the Invention

The present invention encompasses methods for assessing the immune, inflammatory, or malignant status of human patients, which comprise measuring the levels of soluble CD40 ligand (sCD40L) in serum or other body fluids. Patients to which the methods of the invention may be applied include without limitation patients suffering from systemic autoimmunity or inflammation, vascular diseases, viral diseases, or malignancies, or patients undergoing immunosuppressive therapy.

In one aspect, the invention provides methods for monitoring autoimmune, inflammatory, malignant, or vascular disease activity in a patient, which are carried out by the steps of:

- (a) establishing a statistically significant correlation between sCD40L levels in serum or other body fluids and the presence and/or severity of a particular autoimmune, inflammatory, malignant, viral, or vascular disease;
- (b) measuring the sCD40L level in the patient's serum or other  
5 body fluid; and
- (c) determining whether the measured sCD40L level corresponds to a level correlated with the disease, and, if so, corresponds to a level correlated with mild or severe forms of the disease. In one set of embodiments, sCD40L levels are measured in a patient previously diagnosed as suffering from a particular autoimmune, malignant,  
10 vascular or inflammatory disease. In another embodiment, sCD40L levels are measured in a patient who has undergone an organ transplant or is otherwise at risk for graft versus host disease. In yet another embodiment, sCD40L levels are measured to detect previously undiagnosed autoimmune, malignant, viral, vascular or inflammatory disease activity in a patient.
- 15 Diseases to which the methods of the present invention can be applied include without limitation immune system diseases such as, e.g., systemic lupus erythematosus (SLE), Wegener's granulomatosis, polyarteritis nodosa, cryoglobulinemic vasculitis, Sjogren's syndrome, mixed connective tissue disease, glomerulonephritis; conditions of systemic inflammation such as may be present, e.g., in patients undergoing  
20 chronic hemodialysis; malignancies such as, e.g., B cell leukemias and lymphomas; and, vascular damage. Methods for measuring sCD40L include without limitation immunoassays, receptor-binding assays, and biological activity assays.

In another aspect, the invention provides methods for monitoring the efficacy of immunosuppressive therapy in a patient undergoing such therapy. The methods are  
25 carried out by the steps of:

- (a) establishing a statistically significant correlation between sCD40L levels and clinical response, or lack thereof, to immunosuppressive therapy;
- (b) measuring the sCD40L level in the patient; and,
- (c) determining the correspondence between the sCD40L level measured in the patient and the sCD40 levels correlated to response, or lack of response, to immunosuppressive therapy.

Immunosuppressive therapies to which the monitoring methods of the present invention can be applied include without limitation administration of: cyclosporin A; metalloproteinase inhibitors; any agent that alters the transcription or translation of CD40L, the enzymatic processing of the full length form of CD40L to the soluble, secreted form, or the clearance of sCD40L from body fluids; treatments that block the binding of CD40L to the cell surface, such as administration of soluble CD40L, monoclonal antibodies, small molecular inhibitors or soluble receptors; or treatments that ablate malignant cell populations expressing CD40L.

15

#### **Brief Description of the Drawings**

Figure 1 is a histogram showing the kinetics of CD40L expression on peripheral blood mononuclear cells as a function of time after activation with the phorbol ester PMA and ionomycin. CD40L expression was measured by indirect immunofluorescence and flow cytometry, and the results are expressed as mean channel fluorescence (MCF) of the population of cells above the background fluorescence. CD40L expression was measured in normal subjects, SLE patients, and disease control patients.

Figure 2 is a histogram showing CD40L expression on peripheral blood lymphocytes in the absence of activation. Results are expressed as the percentage of CD40L-positive cells after subtraction of background.

Figure 3 is a graphic illustration of CD40L expression on untreated CD4-positive normal and SLE T-cells. Cells were analyzed by multiparameter flow cytometry after a 6 h incubation with medium alone or with the phorbol ester (PMA) and ionomycin. The left panels show CD4 expression on the Y axis and CD40L expression on the X axis. The right panels show histograms indicating the fluorescence intensity on the CD4-positive T-cells.

Figure 4 is a graphic illustration of fluorescence-activated cell sorting (FACS) analysis of CD40L expression on purified B cells that were obtained from 12 different patients suffering from chronic lymphocytic leukemia (CLL). CD40L expression is indicated by the black line. Background immunofluorescence, defined using an irrelevant monoclonal antibody, is shown by the shaded area.

Figure 5A is a graphic illustration of a standard curve of an ELISA measuring CD40L present in cytosolic extracts derived from D1.1 Jurkat T-cells.

Figure 5B is a graphic illustration of a standard curve of an ELISA measuring purified, recombinant human CD40L.

Figure 6A is a graphic illustration of CD40L levels as measured by ELISA in a cytosolic extract of D1.1 Jurkat T-cells (squares) and in sera from two patients suffering from SLE (triangles and circles). Serum samples were incubated for 16 h with increasing concentrations of anti-CD40L monoclonal antibody prior to the ELISA.

Figure 6B is a graphic illustration of CD40L levels as measured by ELISA in serum from a patient with SLE (upward triangles and circles) and a normal subject (downward triangles and squares). Serum samples were incubated for 16 h with increasing



concentrations of anti-CD40L monoclonal antibody (circles and squares) or an irrelevant antibody (triangles) prior to the ELISA.

Figure 7 is a graphic illustration of CD40L levels, as measured by ELISA, in serum samples obtained from patients suffering from SLE, inflammatory diseases  
5 (disease controls, DC), or healthy subjects (NC).

Figure 8A is a table documenting the mean concentration of soluble CD40L, measured by ELISA, in serum samples from normal subjects, SLE patients, and patients serving as disease controls.

Figure 8B is a table showing the association between the concentration of  
10 soluble CD40L in serum and the severity of disease in patients with SLE.

Figure 8C is a table showing the association between concentration of soluble CD40L and the presence of atherosclerosis or a history of arterial thrombosis in patients suffering from antiphospholipid antibody syndrome.

Figure 9 is a graphic illustration of serum concentrations of soluble CD40L  
15 in serum from SLE patients with severe disease, patients with moderate disease, and SLE patients with mild disease.

Figure 10 is a photographic illustration of an immunoblot showing the detection of a soluble CD40L in serum from 3 of 4 patients with SLE or inflammatory disease. The 18KDa band corresponding to sCD40L was visualized using a rabbit anti-  
20 CD40L antiserum.

Figure 11A is a graphic illustration of FACS analysis of the induction of Fas (CD95) expression by sCD40L. Ramos B cells derived from a patient with Burkitt's lymphoma were incubated for 48 hours with culture medium alone ("medium"), with supernatant from 293 cells transfected with CD40L ("293-CD40L"), or with supernatant  
25 from 293 cells expressing CD8 ("293-CD8"). Fas expression was measured by direct

immunofluorescence using a fluorescein-labeled anti-Fas antibody. The percentage of cells that were determined to be Fas-positive is indicated on each histogram.

Figure 11B is a graphic illustration of FACS analysis demonstrating a dose response of Fas expression on Ramos B cell line cells cultured for 48 hours with varying concentrations of recombinant human CD40L. The concentrations of recombinant CD40L that increased Fas expression are in the range observed in sera of patients with systemic autoimmune and inflammatory diseases. The percentage of cells that were determined to be Fas positive is indicated on each histogram.

Figure 12 is a graphic illustration of CD40L levels, as measured by ELISA, in the sera of nine patients suffering from chronic renal disease. Serum samples were obtained before initiation of treatment with cyclosporin A and five days subsequently.

### Detailed Description of the Invention

All patent applications, patents, and literature references cited in this specification are hereby incorporated by reference in their entirety. In the case of inconsistencies, the present description, including definitions, will control.

The present invention is based on the present inventors' discovery that: (i) a soluble form of CD40L, designated sCD40L (Graf et al., *Eur.J.Immunol.* **25**:1749, 1995; Pictravalle et al., *J.Biol.Chem.* **271**:5965, 1996), can be detected in the serum of patients suffering from autoimmune diseases; and (ii) the levels of sCD40L measured in human serum reflect autoimmune disease activity. Furthermore, the present inventors have discovered that CD40L is expressed on the surface of malignant cells such as, e.g., B cell malignancies. According to the present invention, autoimmune, inflammatory, malignant, or vascular disease activity, as well as the efficacy of immunosuppressive therapies, can be monitored by measuring levels of sCD40L in one or more body fluids of a patient,

preferably in serum. The measured levels are then compared with pre-determined sCD40L levels that have been shown to be correlated in a statistically significant fashion with disease activity or response to immunosuppressive therapies.

The present invention encompasses the establishment of such statistically significant correlations, where they exist. To achieve this, sCD40L levels in a large number of patients suffering from a particular autoimmune, inflammatory, malignant, or vascular disease are determined, and are compared with sCD40L levels in control (i.e., healthy) patients that have been matched for age, sex and ethnic origin. A statistical method such as a 2x3 Chi square test is then used to determine whether the sCD40L levels in the disease and normal groups are the same or different. In this manner, it is possible to obtain statistically significant correlations between a given pathological syndrome and sCD40L levels in one or more body fluids. Such correlations are believed to provide an important indicator of disease status and clinical outcome.

Diseases to which the methods can be applied include without limitation systemic lupus erythematosus (SLE), systemic vasculitides such as Wegener's granulomatosis, polyarteritis nodosa, and cryoglobulinemic vasculitis; Sjogren's syndrome; mixed connective tissue disease; graft-versus-host disease (including, e.g., the response of a host to bone marrow or cardiac transplantation); progressive systemic sclerosis or CREST syndrome; pseudogout; kidney diseases such as glomerulonephritis; systemic inflammatory conditions such as those suffered by patients on chronic hemodialysis; progressive systemic sclerosis; pseudogout; vascular disease, such as, e.g., atherosclerosis and arterial thrombosis, including without limitation that exhibited in patients with antiphospholipid antibody syndrome; malignancies of cells that express CD40L, such as CLL; and any acute or chronic viral infection that is characterized by T cell activation, such as, e.g., an

infection caused by cytomegalovirus (CMV), human immunodeficiency virus (HIV), hepatitis virus (particularly hepatitis B or C), and herpesviruses.

The clinical manifestations of these diseases range from mild to severe. Mild disease encompasses symptoms that may be function-altering and/or comfort-altering, but are neither immediately organ-threatening nor life-threatening. Severe disease entails organ-threatening and/or life-threatening symptoms. For example, severe autoimmune disease is often associated with clinical manifestations such as nephritis, vasculitis, central nervous system disease, premature atherosclerosis or lung disease, or combinations thereof, that require aggressive treatment and may be associated with premature death. Anti-phospholipid antibody syndrome is often associated with arterial or venous thrombosis. Malignancies, such as CLL, are associated with immune system abnormalities such as autoantibody production. Any statistically significant correlation that is found to exist between serum sCD40L levels and any clinical parameters of an autoimmune, inflammatory, vascular, viral, or malignant disease would enable the use of a serum sCD40L assay as part of a diagnostic battery for that disease or group of diseases.

Diseases can exhibit ranges of activities. As used herein, disease activity refers to whether the pathological manifestations of the disease are fulminant, quiescent, or in a state between these two extremes. For example, a patient suffering from SLE having active disease would manifest a comparatively low level of serum complement, whereas a patient having inactive disease would manifest comparatively higher or normal level of serum complement. It will be understood that each of the diseases encompassed by the invention can be evaluated using known staging parameters well-known to those of ordinary skill in the art (Harrison's *Principles of Internal Medicine*.)

In practicing the present invention, sCD40L levels in an individual patient are measured in one or more body fluids, including without limitation plasma, serum,

urine, saliva, synovial fluid, cerebrospinal fluid, and the like. sCD40L is measured using any appropriate method, including without limitation: immunoassays that measure sCD40L immunoreactive material; receptor binding assays that measure the interaction of sCD40L with CD40; and biological activity assays that measure a physiological consequence of CD40L-CD40 interaction.

Immunoassays useful for measuring sCD40L include without limitation radioimmunoassays; ELISA; and Western blotting. The anti-sCD40L antibodies used in these assays may be polyclonal or monoclonal; the only requirement is that they bind sCD40L with sufficient affinity and specificity to enable the measurement of sCD40L in the particular assay conditions used. The antibodies may be used without purification, or may be purified by standard methods, as disclosed in, e.g., in *The Art of Antibody Purification*, 1989, Amicon Division, W.R. Grace & Co. Immunoassay methods are disclosed in, e.g., *Immunochemical Methods in Cell and Molecular Biology*, 1987 (Mayer and Waler, eds; Academic Press, London); and *Handbook of Experimental Immunology*, 1986, Volumes I-IV (Weir and Blackwell eds.) An example of an ELISA that measures sCD40L is described in detail in Example 3 below.

Receptor binding assays typically employ native CD40 and measure the ability of a sample to compete with radiolabelled sCD40L for binding to CD40. CD40 for use in the assay may be present on native B cells that display CD40 on their cell surface, or cells that have been programmed to express CD40 using recombinant DNA technology. Alternatively, the assay may employ purified CD40 isolated from a native or recombinant source. Fragments of CD40 that retain the capacity to bind sCD40L may also be used; such fragments may be derived from CD40 proteolytically or may result from expression of a truncated CD40 gene. In addition, variant forms of CD40L that retain CD40-binding capacity may be used. The nucleotide and amino acid sequence of CD40L is disclosed

in Graf et al., *Eur. J. Immunol.* 22:3191, 1992; and Shimadzu et al., *Biochim. Biophys. Acta* 1260:67, 1995. Recombinant expression of wild-type and variant CD40L is disclosed in, e.g., Bajorath et al., *Biochemistry* 34:1833, 1995; and Bajorath et al., *Biochemistry* 34:9884, 1995. Techniques for recombinant expression and/or purification of full-length and truncated CD40 are well known and are explained fully in, e.g., Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; *DNA Cloning: A Practical Approach*, Volumes I and II, 1985 (D.N. Glover ed.); and Scopes, 1987, *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.).

10                   Biological activity assays for use in the present invention measure cellular responses to the functional interaction of sCD40L with CD40, including without limitation: stimulation of B-cell proliferation; induction of B-cell surface activation, adhesion, and co-stimulatory molecules, such as, for example, CD23, CD54, CD80, CD86, CD95 and MHC Class II; B-cell stimulation of allogeneic T-cell proliferation; antibody production; 15 immunoglobulin class switching; stimulation of endothelial cells or fibroblasts to express adhesion molecules; and stimulation of macrophages or dendritic cells to express cell surface activation molecules or cytokines such as interleukin-12. Typically, the biological activity of a sample is measured before and after incubation with neutralizing amounts of anti-CD40L antibody, and the difference between the two measurements reflects sCD40L- 20 mediated activity.

It will be understood that any statistically significant correlation between disease activity and sCD40L levels that is established using a particular sCD40L assay technique can be extended to sCD40L levels measured using an alternative technique. This is achieved, for example, by establishing a secondary correlation between sCD40L levels

measured using an ELISA or radioimmunoassay and those measured using a receptor-binding or biological activity assay.

In a preferred embodiment, serum sCD40L levels are measured by ELISA using a mouse monoclonal antibody specific for human CD40L. Using this assay, serum sCD40L levels in normal subjects were found to be <200 pg/ml, while the levels in patients with active SLE ranged from about 5000 to about 30,000 pg/ml (See Example 4 below). Accordingly, the measurement of a serum sCD40L level greater than about 3 standard deviations above the mean of population of normal control subjects provides a useful diagnostic indicator of active SLE. Measurement of a serum sCD40L level between about 1-3 standard deviations above the mean of a population of normal subjects provides a useful diagnostic indicator of the presence of autoimmune disease in general, including inactive SLE, vasculitis, or other conditions of systemic inflammation. It was also found that serum sCD40L levels declined markedly following initiation of cyclosporin A treatment (see Example 7 below). Accordingly, the measurement of a decline in serum sCD40L levels provides a useful diagnostic indicator of clinical response to immunosuppressive therapy.

Immunosuppressive therapies to which the monitoring methods of the present invention can be applied include without limitation administration of: cyclosporin A; metalloproteinase inhibitors; any agent that alters the transcription or translation of CD40L, the enzymatic processing of the full length form of CD40L to the soluble, secreted form, or the clearance of sCD40L from body fluids; treatments that absorb or block the binding of CD40L to the cell surface, such as soluble CD40L, monoclonal antibodies, small molecular inhibitors or soluble receptors; or treatments that ablate malignant cell populations expressing CD40L.

The following working examples are intended to serve as non-limiting illustrations of the present invention.

**Example 1: Increased Expression of CD40L in Patients with Systemic Lupus Erythematosus (SLE)**

The following experiments were performed to examine the level and kinetics of expression of CD40L on peripheral blood lymphocytes derived from normal, disease control, and SLE individuals. "Disease control" patients include those with seropositive rheumatoid arthritis, progressive systemic sclerosis, Reiter's syndrome, and autoimmune thyroid disease.

Peripheral blood mononuclear cells (PBMC) isolated by Ficoll-hypaque were cultured for 6, 24, or 48 hours in the presence of 5 ng/ml of the phorbol ester (PMA) and 500 ng/ml ionomycin, after which they were stained with anti-CD40L antibody and a fluorescent second antibody. CD40L levels were quantified by flow cytometry and expressed as the mean channel fluorescence (MCF) of the population of gated cells above the upper limit of the background fluorescence (Figure 1). As a control, CD25 (Tac) expression was quantified in parallel.

While activated cell populations from healthy subjects (n=14) and disease control patients (n=8) show maximal MCF of CD40L after 6 h of culture, with a gradual decrease to near baseline levels at 48 h of culture, activated lymphocytes from SLE patients (n=19) continue to demonstrate high CD40L levels at 24 and 48 h (p= 0.01 and 0.038 at 24 h, respectively, when compared with normal subjects, and p= 0.035 and 0.042 at 24 and 48 h, respectively, when compared with disease controls). By contrast, the kinetics and absolute levels of CD25 expression were comparable in normal control and SLE cells, with the MCF gradually increasing over 48 h of culture. Notably, expression



of CD40L on untreated PBMC was increased in some of the SLE patients (Figure 2).

Three of the SLE patients with the highest baseline expression of CD40L had renal disease, suggesting that this phenomenon is related to disease activity. Multiparameter fluorescence analysis showed CD40L on untreated CD4+ T cells (Figure 3).

5                   These data indicate that both SLE and normal T helper cells rapidly express high levels of CD40L in response to activation by PMA and ionomycin. In normal subjects, CD40L is quickly downregulated and nearly gone from the cell surface by 48 h; in SLE patients, by contrast, T cells show prolonged high level expression of CD40L for more than 24 h. In addition, lymphocytes from patients with active SLE express some  
10   CD40L even in the absence of *in vitro* activation.

**Example 2: Increased expression of CD40L in Patients with Chronic Lymphocytic Leukemia**

The following experiments were performed to examine the level of  
15   expression of CD40L on purified peripheral blood B lymphocytes derived from individuals suffering from CLL.

Peripheral blood B cells were purified from whole blood by Ficoll-Hypaque and T cells were removed from the preparation by rosetting with sheep red blood cells. CD40L levels were quantified by flow cytometry as described in Example 1. As a control,  
20   the cells were stained with an irrelevant isotype matched monoclonal antibody to the human TCRV $\beta$ 13 chain.

The results are shown in Figure 4. The CD40L pattern is indicated by the thick black line, while the control pattern is indicated by the shaded grey area. The results indicate that the B cells from 11 of 12 patients with CLL exhibit higher than control  
25   expression of CD40L.

**Example 3: Detection of Soluble CD40L by ELISA**

The method described below is used to measure sCD40L in samples comprising human serum or other body fluid.

**A. ELISA PROTOCOL:**

- 5                   1. 96-well microwell plates are coated with a mouse monoclonal anti-human CD40L antibody (Pharmingen, San Diego, CA). 50  $\mu$ l of the antibody at a final concentration of 1 ng/ $\mu$ l in 50 mM sodium carbonate buffer is added to each well, and the plate incubated overnight at 4°C. The plate is then washed in phosphate buffered saline containing 0.01% (v/v) Tween-20 (PBS-T), and blocked by incubation with PBS-T  
10                   containing 10% milk for 2 h at room temperature.
2. 50  $\mu$ l of the sample to be measured is added to a well, after which the plate is incubated at 37°C for 4 h or overnight at 4°C. The plate is then washed three times with PBS-T.
3. 50  $\mu$ l of 1:1000 dilution of alkaline phosphate-conjugated mouse  
15                   monoclonal anti-human CD40L (Ancell, Bayport MN) is then added to each well, after which the plate is incubated at 37°C for 2 h. The plate is then washed three times with PBS-T.
4. 50  $\mu$ l of developing substrate (prepared by dissolving two tablets of Sigma 104 phosphate substrate in 10 ml diethanolamine) is added per well and the plate  
20                   is incubated in the dark at 37°C for 15 min. The absorbance at 405 nm is then measured in an automated ELISA reader.

**B. SAMPLES:**

1. To generate a standard curve, cytosolic extracts of the D1.1 CD40L-positive Jurkat T-cell line or recombinant human CD40L were added in concentrations ranging from 3-400 pg/ml protein.

2. Negative controls included cytosolic extracts of the B2.7 CD40L-negative Jurkat T-cell line, as well as PBS as a buffer control.

**C. RESULTS:**

Figures 5A and 5B show that the ELISA described above readily detects CD40L in D1.1 cell lysates over a range of concentrations and also detects purified recombinant human CD40L. The specificity of the assay was demonstrated by pre-incubating the D1.1 cell lysate with increasing concentrations of an anti-CD40L monoclonal antibody (Figure 6A, squares), which reduced the detection of sCD40L by the assay. Similar pre-incubation of sera from two patients with SLE also reduced the detection of sCD40L (Figure 6A, triangles and circles). Incubation of SLE serum with an irrelevant antibody (anti-CD71), by contrast, had no effect on CD40L detection by the assay (Figure 6B).

**Example 4: Increased Soluble CD40L in Serum from SLE Patients**

Serum samples were collected from healthy ("normal") subjects; "disease controls" (including patients suffering from rheumatoid arthritis, anti-phospholipid syndrome, Lyme disease, and osteoarthritis); patients with systemic vasculitis (including polyarteritis nodosa, Wegener's granulomatosis, and hepatitis B and C-related vasculitis); and patients with SLE, including active and inactive SLE. (SLE was deemed active if renal involvement, central nervous system disease was documented). Serum sCD40L levels were then measured using the ELISA described in Example 3 above.

The results indicate that the distribution of serum sCD40L levels differs significantly among the different patient groups. Serum sCD40L levels in SLE patients were significantly increased relative to controls, ranging from 1000-30,000 pg/ml (Figure 7 and Figure 8A). Furthermore, serum sCD40L levels were significantly higher in patients with active SLE than those with inactive SLE (Figure 8B and Figure 9).

These data demonstrate that the levels of sCD40L in the serum of patients can serve as a useful diagnostic indicator of SLE disease activity.

**Example 5: Demonstration of Soluble CD40L in Sera from SLE Patients by Immunoblotting**

The following experiments were designed to demonstrate the use of immunoblotting to determine the amount and molecular mass of soluble CD40L in serum. Sera from patients with SLE were subjected to immunoprecipitation with anti-CD40L monoclonal antibody, after which the immune complexes separated by electrophoresis and transferred to a membrane. Soluble CD40L was visualized by immunoblotting using as a primary antibody rabbit anti-CD40L antiserum. Bound antibody was detected using a chemiluminescence kit.

The results indicated that a protein species having a molecular mass of 18kDa, corresponding to soluble CD40L, could be detected in serum from 3 of 4 patients with SLE or inflammatory disease (Figure 10). No 18kDa species, however, was detected in sera from 3 normal subjects.

**Example 6: Soluble CD40L Induces Expression of Activation Antigens on B Cells**

The experiments described below were performed to determine whether soluble CD40L induces expression of activation antigens, such as, e.g., the Fas antigen, on

target cells. Ramos B cells, derived from a patient with Burkitt's lymphoma, were incubated for 48 hours with culture medium alone, with supernatant from 293 cells expressing CD40L, or with supernatant from 293 cells expressing CD8. Fas (CD95) expression was measured on the Ramos B cells by flow cytometry using a fluorescein-labeled anti-CD40L antibody.

The results indicated that incubation with supernatant from CD40L expressing cells increased the expression of Fas antigen on the target cells (Figure 11A). Furthermore, purified recombinant CD40L was shown to increase Fas expression in a dose-dependent manner (Figure 11B).

10

**Example 7: Correlation of Serum sCD40L Levels and Response to Immunosuppressive Therapy**

The following experiment were performed to evaluate the possible relationship between serum sCD40L levels and response to immunosuppressive therapy.

Serum samples were obtained from nine patients suffering from chronic renal disease (i) before initiation of cyclosporin A treatment and (ii) five days after initiation of cyclosporin-A treatment at 10-14 mg/kg/day. Serum sCD40L levels were measured using ELISA as described in Example 3 above.

The results demonstrate that serum sCD40L levels decreased markedly in all of the patients subsequent to cyclosporin A treatment (Figure 12). These data indicate that serum sCD40L levels can serve as a useful diagnostic indicator of the efficacy of immunosuppressive therapies.

**Claims:**

1                   1.     A diagnostic method for monitoring disease activity in a patient  
2     suffering from an autoimmune, inflammatory, malignant, vascular, or viral disease, which  
3     comprises:

4                   (a)     establishing a statistically significant correlation between  
5     sCD40L levels in a body fluid and the presence or severity of a particular autoimmune or  
6     inflammatory disease;

7                   (b)     measuring the sCD40L level in a body fluid of the patient;  
8     and

9                   (c)     determining whether the measured sCD40L level corresponds  
10    to a level correlated with presence or severity of the disease.

1                   2.     A method as defined in claim 1, wherein said disease is selected  
2     from the group consisting of: systemic lupus erythematosus (SLE), Wegener's  
3     granulomatosis, polyarteritis nodosa, cryoglobulinemic vasculitis, Sjogren's syndrome,  
4     mixed connective tissue disease, graft-versus-host disease, glomerulonephritis, vascular  
5     disease, thrombosis, progressive systemic sclerosis, pseudogout, malignancies of cells that  
6     express CD40L, and infection with a virus selected from the group consisting of  
7     herpesvirus, hepatitis virus, Human Immunodeficiency Virus, and cytomegalovirus.

1                   3.     A method as defined in claim 1, wherein said measuring is achieved  
2     using a method selected from the group consisting of immunoassay, receptor-binding assay,  
3     and biological activity assay.

1                   4.     A method as defined in claim 1, wherein said body fluid is selected  
2 from the group consisting of plasma, serum, urine, saliva, synovial fluid, and cerebrospinal  
3 fluid.

1                   5.     A diagnostic method for monitoring the severity of an autoimmune,  
2 inflammatory, vascular, malignant, or viral disease in a patient suffering from an  
3 autoimmune, inflammatory, vascular, malignant, or viral disease, which comprises:

4                   (a)     establishing a statistically significant correlation between  
5 sCD40L levels in a body fluid and the presence of mild or severe forms of said disease;

6                   (b)     measuring the sCD40L level in a body fluid of the patient;  
7 and

8                   (c)     determining whether the measured sCD40L level corresponds  
9 to a level correlated with mild or severe forms of the disease.

1                   6.     A method as defined in claim 5, wherein said disease is selected from  
2 the group consisting of: systemic lupus erythematosus (SLE), Wegener's granulomatosis,  
3 polyarteritis nodosa, cryoglobulinemic vasculitis, Sjogren's syndrome, mixed connective  
4 tissue disease, graft-versus-host disease, glomerulonephritis, vascular disease, thrombosis,  
5 progressive systemic sclerosis, pseudogout, malignancies of cells that express CD40L, and  
6 infection with a virus selected from the group consisting of herpesvirus, hepatitis virus,  
7 Human Immunodeficiency Virus, and cytomegalovirus.

8                   7.     A method as defined in claim 6, wherein said disease is SLE.

9                   8.     A method as defined in claim 6, wherein said disease is chronic  
10 lymphocytic leukemia (CLL).

1                   9.     A method as defined in claim 5, wherein said measuring is achieved  
2 using a method selected from the group consisting of immunoassay, receptor-binding assay,  
3 and biological activity assay.

1                   10.    A method as defined in claim 5, wherein said body fluid is selected  
2 from the group consisting of plasma, serum, urine, saliva, synovial fluid, and cerebrospinal  
3 fluid.

1                   11.    A diagnostic method for monitoring the efficacy of  
2 immunosuppressive therapy in a patient, which comprises:  
3                   (a)     establishing a statistically significant correlation between  
4 sCD40L levels in a body fluid and clinical response, or lack thereof, to said  
5 immunosuppressive therapy;  
6                   (b)     measuring the sCD40L level in a body fluid of a patient  
7 undergoing immunosuppressive therapy; and  
8                   (c)     determining the correspondence between the sCD40L level  
9 measured in the patient and the sCD40 levels correlated to response, or lack of response,  
10 to said immunosuppressive therapy.

1                   12.    A method as defined in claim 11, wherein said measuring is  
2 achieved using a method selected from the group consisting of immunoassay, receptor-  
3 binding assay, and biological activity assay.




1                   13.           A method as defined in claim 11, wherein said body fluid is  
2 selected from the group consisting of plasma, serum, urine, saliva, synovial fluid, and  
3 cerebrospinal fluid.

1                   14.           A method for monitoring severity of SLE in a patient  
2 suffering from SLE, which is carried out by the steps of:  
3                   (a)       establishing a statistically significant correlation between  
4 sCD40L levels in a body fluid and the severity of SLE;  
5                   (b)       measuring the sCD40L level in the patient's body fluid; and  
6                   (c)       determining whether the measured sCD40L level corresponds  
7 to mild or severe forms of SLE.

8                   15.           A method for monitoring severity of vascular disease in a  
9 patient suffering from vascular disease, which is carried out by the steps of:  
10                  (a)       establishing a statistically significant correlation between  
11 sCD40L levels in a body fluid and the severity of vascular disease;  
12                  (b)       measuring the sCD40L level in the patient's body fluid; and  
13                  (c)       determining whether the measured sCD40L level corresponds  
14 to mild or severe forms of vascular disease.


1/22

FIG. 1A




2/22

FIG. 1B




3/22

FIG. 1C



4/22

FIG. 2



5/22

FIG. 3 A





FIG. 3 B



SUBSTITUTE SHEET (RULE 26)

6/22

FIG. 3C





FIG. 3D



7/22

FIG. 3E





FIG. 3F





8/22

FIG. 3 G







FIG. 3 H



9/22



10/22

FIG. 4H




FIG. 4J




FIG. 4L





FIG. 4G



FIG. 4I




FIG. 4K



11/22


FIG. 5A





SUBSTITUTE SHEET (RULE 26)

12/22

FIG. 5B




13/22



14/22

FIG. 7



15/22

FIG. 8A

SUBJECT GROUP	MEAN SOLUBLE CD40 LIGAND (ng/ml)
Normal Subjects (n = 22)	0.23 ± 0.14
SLE Patients (n = 60)	9.13 ± 6.26
Disease Control Subjects (n = 30)	2.71 ± 3.16
- Rheumatoid Arthritis (n = 9)	2.26 ± 3.93
- Wegener's Granulomatosis (n = 7)	3.17 ± 2.71
- Antiphospholipid Antibody Syndrome (n = 6)	7.92 ± 5.56
- Others (n = 14)	2.76 ± 3.04

FIG. 8B

DISEASE SEVERITY OF SLE PATIENTS	MEAN SOLUBLE CD40 LIGAND (ng/ml)
Severe (nephritis and/or central nervous system)	12.09 ± 6.94
Moderate (mild/moderate proteinuria or low C')	7.93 ± 3.86
Mild (no clinical organ involvement)	5.28 ± 3.90




16/22

FIG. 8C

Serum CD40L in patients with APL and a history of arterial thrombosis or evidence of atherosclerosis on carotid doppler (ng/ml)	Serum CD40L in patients with APL and no history of arterial thrombosis and no evidence of atherosclerosis on carotid doppler (ng/ml)
11.9	3.9
7.7	3.9
12.0	0.7
12.1	-
14.3	-

17/22


FIG. 9



SUBSTITUTE SHEET (RULE 26)

18/22

## FIG. 10



SUBSTITUTE SHEET (RULE 26)

19/22




FIG. IIA

Medium




FIG. IIB

293-CD40L




FIG. IIC

293-CD8




FIG. IIF




FIG. IIE




FIG. IID

FIG. 11G






FIG. 11H



22/22

FIG. 12



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/20540

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/02; G01N 33/564, 33/566, 33/569, 33/574

US CL : 435/5, 7.21, 7.23, 7.24, 7.8, 29; 436/501, 506

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/5, 7.21, 7.23, 7.24, 7.8, 29; 436/501, 506

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS: solub?(2a)(cd40(w)ligand or cd40L or cd154) or scd40(w)ligand or scd40L or scd154

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VAKKALANKA, R.K. et al. Increased levels of soluble CD40 ligand in sera from patients with systemic lupus erythematosus. Arthritis & Rheumatism. September 1996, Volume 39, Number 9(Supplement), page S35, column 2, abstract number 52, see entire abstract.	1-14
X	MACDONALD, K. et al. Functional membrane and soluble forms of CD40-ligand in rheumatoid arthritis. Arthritis & Rheumatism, September 1996, Volume 39, Number 9(Supplement), page S159, column 2, abstract number 793, see entire abstract.	1,3-5,9-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents	* T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* &* document member of the same patent family
* C* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 JANUARY 1998

Date of mailing of the international search report

23 FEB 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID SAUNDERS

Telephone No. (703) 308-0196